Back to Results

Kamada Ltd (KMDA)

Kamada Ltd. is a biotechnology company engaged in the manufacture and sale of plasma-derived protein therapeutics. Its portfolio includes products used in areas such as rabies prophylaxis, transplant-related Cytomegalovirus prevention, varicella post-exposure prophylaxis, immune thrombocytopenic purpura, hepatitis B prevention, alpha-1 antitrypsin deficiency, and treatment of snake bites. The company also distributes a range of biopharmaceutical products in Israel, covering respiratory, immunology, hematology, infectious disease, and oncology-related therapies. Founded in 1990 and headquartered in Rehovot, Israel, Kamada’s common stock is listed on the NASDAQ exchange under the symbol KMDA.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-KMDA
$10
12.8% Upside
Fair
$13.50
52.2% Upside
Bargain
Great
1.9%
November 16, 2026
22.7x
1.9x
2.6x
504.6 M
446.8 M
2.3%
54.9%
10.0
64.8%
118.3%
Valuation • Fair Value

Kamada Ltd (NASDAQ-KMDA) Fair Value by Valuation Model

Review the available estimates for Kamada Ltd (NASDAQ-KMDA), including DCF Fair Value, Ben Graham Formula Value, DDM Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$10

Estimated upside of 12.8% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$12.77

Discounted cash flow valuation reference.

Ben Graham Formula Value

$4.28

Classic Ben Graham valuation formula reference.

DDM Fair Value

$9.77

Dividend discount model valuation reference.

EPV Fair Value

$5.58

Earnings power value estimate.

Comps Fair Value

$8.01

Comparable-company valuation reference.

Analyst Price Target

$13.50

Analysts imply upside of 52.2%.

How to read these valuation models

Use the 8 available valuation references for Kamada Ltd (NASDAQ-KMDA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Kamada Ltd (NASDAQ-KMDA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

191.8 M

Current operating scale indicator.

Revenue Forecast

199.2 M

Forward revenue estimate.

EBITDA

41.494 M

Current operating profitability reference.

EBITDA Forecast

50.128 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Kamada Ltd (NASDAQ-KMDA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Kamada Ltd (NASDAQ-KMDA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-2.46

No elevated caution signal from this screen.

Altman Z-Score

10.0

Relatively strong balance-sheet zone.

FCF / Net Income

118.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Kamada Ltd (NASDAQ-KMDA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Kamada Ltd (NASDAQ-KMDA)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 16, 2026

Days to Earnings

55

Dividend Yield

1.9%

Current income yield reference.

Payout Ratio

64.8%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Kamada Ltd (NASDAQ-KMDA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Kamada Ltd (NASDAQ-KMDA) Stock Forecast & Technical Outlook

Review Kamada Ltd (NASDAQ-KMDA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Kamada Ltd (NASDAQ-KMDA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Kamada Ltd (NASDAQ-KMDA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Kamada Ltd (NASDAQ-KMDA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Kamada Ltd (NASDAQ-KMDA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Kamada Ltd (NASDAQ-KMDA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Kamada Ltd (NASDAQ-KMDA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Kamada Ltd (NASDAQ-KMDA) has a Strong Buy consensus, with 3 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 0
Sell 0
FAQ • Fast Investor Answers

Kamada Ltd (NASDAQ-KMDA) Stock FAQ

Data-supported answers about Kamada Ltd (NASDAQ-KMDA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$10
Estimated upside 12.8%
Valuation Rating
Undervalued
Estimated upside of 12.8%
Analyst Target
$13.50
Implied upside 52.2%
Financial Health
Great
Current financial-health read

The current fair value estimate for Kamada Ltd (NASDAQ-KMDA) is $10. This implies an estimated upside of 12.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 12.8% versus the current market price.

The available analyst price target for Kamada Ltd (NASDAQ-KMDA) is $13.50. The analyst target implies estimated upside of 52.2%.

The current financial health read for Kamada Ltd (NASDAQ-KMDA) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Kamada Ltd (NASDAQ-KMDA) is November 16, 2026.

Based on the current data, dividend yield is 1.9%.

The current P/E ratio listed for Kamada Ltd (NASDAQ-KMDA) is 22.7x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Kamada Ltd is 504.6 M.

The current enterprise value listed for Kamada Ltd is 446.8 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Kamada Ltd is NASDAQ-KMDA, and the stock is listed on NASDAQ.

Kamada Ltd (NASDAQ-KMDA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Kamada Ltd is 2.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Kamada Ltd is 54.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B